Tumor Markers: Clinical Applications and Specific Malignancy Associations
Tumor markers should NOT be used for screening or diagnosis in most cancers, but are valuable for surveillance after curative treatment and monitoring response to therapy in metastatic disease.
Key Principle: Limited Diagnostic Utility
Tumor markers have poor sensitivity and specificity for cancer diagnosis and should never establish a diagnosis alone 1, 2. Their primary clinical value lies in monitoring known disease, not detecting new disease 3, 4.
Colorectal Cancer: CEA
Surveillance After Curative Treatment
- Measure CEA every 3 months for at least 3 years in stage II or III disease if the patient is a candidate for surgery or systemic therapy 5
- Wait until chemotherapy is finished before initiating CEA surveillance, as chemotherapy may falsely elevate levels 5
- An elevated CEA (confirmed by retesting) warrants further evaluation for metastatic disease but does not justify systemic therapy by itself 5
Monitoring Metastatic Disease
- CEA is the marker of choice for monitoring metastatic colorectal cancer during systemic therapy 5
- Measure at treatment start and every 1-3 months during active treatment 5
- Persistently rising values above baseline suggest progressive disease even without radiographic confirmation 5
- Caution: Spurious early rises may occur during the first 4-6 weeks of new therapy, especially with oxaliplatin 5
NOT Recommended
- CEA should not be used for screening, diagnosis, or staging of colorectal cancer 5
- CA 19-9 has insufficient evidence for any use in colorectal cancer 5
Breast Cancer: CA 15-3 and CA 27.29
Monitoring Metastatic Disease
- CA 15-3 or CA 27.29 can detect recurrence after primary therapy, though sensitivity is only 57.7% with a lead time of 5.3 months 5
- In metastatic disease, CA 27.29 was elevated in 81% of patients; a median increase of 32% correlated with progressive disease 5
- In the absence of readily measurable disease, a rising CEA may suggest treatment failure in breast cancer patients 5
Stage Correlation (Not for Diagnosis)
- Elevation rates increase with stage: 5-30% (stage I), 15-50% (stage II), 60-70% (stage III), and 65-90% (stage IV) 5
- Low levels do not exclude metastases, and a given level cannot determine disease stage 5
NOT Recommended
- CEA should not be used for screening, diagnosis, staging, or routine surveillance of breast cancer 5
Pancreatic Cancer: CA 19-9
Limited Monitoring Role
- CA 19-9 can be measured at treatment start for locally advanced/metastatic disease and every 1-3 months during active treatment 5
- Rising serial CA 19-9 may indicate progressive disease but requires confirmation with imaging or biopsy 5
NOT Recommended
- Not for screening, determining operability, or providing definitive evidence of recurrence alone 5
- Insufficient evidence for routine use in monitoring treatment response 5
Ovarian Cancer: CA-125
Monitoring Therapy
- CA-125 is validated for monitoring therapy in patients with ovarian cancer 3, 4
- Elevated in epithelial cell tumors, carcinosarcoma, teratomas, and secondary ovarian malignancies 6
Diagnosis Support (Not Screening)
- Diagnosis relies on combination of CA-125 levels and ultrasound findings (large adnexal mass, high-risk features like septa and increased vascularity) 6
- CA-125 has limited role in screening and is not recommended for this purpose 1
Other Ovarian Markers
- CA 19-9: Associated with clear cell tumors, teratomas, and secondary malignancies 6
- CEA: Associated with mucinous ovarian cancers 6
- HE4: Increasingly used for serous and endometrioid epithelial ovarian cancers 6
Germ Cell Tumors: AFP and hCG
- AFP and hCG are validated for evaluating prognosis in non-seminomatous germ cell tumors 3, 4
- AFP is also useful for screening in high-risk groups for hepatocellular carcinoma 1
Prostate Cancer: PSA
- PSA is useful for screening in high-risk groups, though its value in reducing mortality from prostate cancer screening remains unclear 3, 1
- Not validated in large prospective randomized trials for screening 4
Predictive Markers
Breast Cancer
- Estrogen receptors: Predict response to hormone therapy 3, 4
- HER-2: Identifies patients likely to respond to trastuzumab (Herceptin) 3, 4
Colorectal Cancer
- KRAS mutational status: Identifies patients with advanced disease likely to benefit from cetuximab and panitumumab 3
Critical Pitfalls to Avoid
- Never diagnose cancer based on tumor markers alone 1, 2
- Never initiate systemic therapy based solely on elevated markers without imaging confirmation 5
- Wait 5-6 half-lives before repeat sampling; if elevated, recheck in 2-4 weeks for confirmation 2
- Beware of false elevations during the first 4-6 weeks of new chemotherapy, particularly with oxaliplatin 5
- Prevalence matters: Sensitivity and specificity vary significantly based on disease prevalence, limiting screening utility 2